These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37003047)

  • 1. Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease.
    Qin T; Gao X; Lei L; Feng J; Zhang W; Hu Y; Shen Z; Liu Z; Huan Y; Wu S; Xia J; Zhang L
    Eur J Med Chem; 2023 Apr; 252():115307. PubMed ID: 37003047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural optimization and biological evaluation of 1-adamantylcarbonyl-4-phenylpiperazine derivatives as FXR agonists for NAFLD.
    Qin T; Gao X; Lei L; Zhang W; Feng J; Wang X; Shen Z; Liu Z; Huan Y; Wu S; Xia J; Zhang L
    Eur J Med Chem; 2023 Jan; 245(Pt 1):114903. PubMed ID: 36375336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pose Filter-Based Ensemble Learning Enables Discovery of Orally Active, Nonsteroidal Farnesoid X Receptor Agonists.
    Xia J; Wang Z; Huan Y; Xue W; Wang X; Wang Y; Liu Z; Hsieh JH; Zhang L; Wu S; Shen Z; Zhang H; Wang XS
    J Chem Inf Model; 2020 Mar; 60(3):1202-1214. PubMed ID: 32050066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and structure-activity relationship studies of novel partial FXR agonists for the treatment of fatty liver.
    Qiu Q; Wang W; Zhao X; Chen Y; Zhao S; Zhu J; Xu X; Geng R
    Bioorg Chem; 2020 Nov; 104():104262. PubMed ID: 32919135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altenusin, a Nonsteroidal Microbial Metabolite, Attenuates Nonalcoholic Fatty Liver Disease by Activating the Farnesoid X Receptor.
    Zheng Z; Zhao Z; Li S; Lu X; Jiang M; Lin J; An Y; Xie Y; Xu M; Shen W; Guo GL; Huang Y; Li S; Zhang X; Xie W
    Mol Pharmacol; 2017 Oct; 92(4):425-436. PubMed ID: 28739572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cycloastragenol improves hepatic steatosis by activating farnesoid X receptor signalling.
    Gu M; Zhang S; Zhao Y; Huang J; Wang Y; Li Y; Fan S; Yang L; Ji G; Tong Q; Huang C
    Pharmacol Res; 2017 Jul; 121():22-32. PubMed ID: 28428116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D-QSAR and Molecular Dynamics Study of Isoxazole Derivatives to Identify the Structural Requirements for Farnesoid X Receptor (FXR) Agonists.
    Yan D; Yang Y; Shen H; Liu Z; Yao K; Liu Q
    Molecules; 2024 Mar; 29(6):. PubMed ID: 38542850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.
    Li J; Liu M; Li Y; Sun DD; Shu Z; Tan Q; Guo S; Xie R; Gao L; Ru H; Zang Y; Liu H; Li J; Zhou Y
    J Med Chem; 2020 Nov; 63(21):12748-12772. PubMed ID: 32991173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesoid X Receptor as a Promising Therapeutic Target for Nonalcoholic Fatty Liver Disease (NAFLD) and the Current Development of Its Agonists.
    Shen T; Shi A; Wei Y; Luo X; Xi L
    Discov Med; 2021; 32(167):113-121. PubMed ID: 35220997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-model in silico characterization of 3-benzamidobenzoic acid derivatives as partial agonists of Farnesoid X receptor in the management of NAFLD.
    Mitra S; Halder AK; Ghosh N; Mandal SC; Cordeiro MNDS
    Comput Biol Med; 2023 May; 157():106789. PubMed ID: 36963353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
    Jadhav K; Xu Y; Xu Y; Li Y; Xu J; Zhu Y; Adorini L; Lee YK; Kasumov T; Yin L; Zhang Y
    Mol Metab; 2018 Mar; 9():131-140. PubMed ID: 29361497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural Products in the Modulation of Farnesoid X Receptor Against Nonalcoholic Fatty Liver Disease.
    Wang J; Yang N; Xu Y
    Am J Chin Med; 2024; 52(2):291-314. PubMed ID: 38480498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
    Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
    J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.
    Chianelli D; Rucker PV; Roland J; Tully DC; Nelson J; Liu X; Bursulaya B; Hernandez ED; Wu J; Prashad M; Schlama T; Liu Y; Chu A; Schmeits J; Huang DJ; Hill R; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Liu B; Richmond W; Sancho-Martinez I; Phimister A; Seidel HM; Badman MK; Joseph SB; Laffitte B; Molteni V
    J Med Chem; 2020 Apr; 63(8):3868-3880. PubMed ID: 31940200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner.
    Han X; Cui ZY; Song J; Piao HQ; Lian LH; Hou LS; Wang G; Zheng S; Dong XX; Nan JX; Wu YL
    Chem Biol Interact; 2019 Sep; 311():108794. PubMed ID: 31421115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Farnesoid X Receptor Deficiency Induces Hepatic Lipid and Glucose Metabolism Disorder via Regulation of Pyruvate Dehydrogenase Kinase 4.
    Deng W; Fan W; Tang T; Wan H; Zhao S; Tan Y; Oware KA; Tan J; Li J; Qu S
    Oxid Med Cell Longev; 2022; 2022():3589525. PubMed ID: 35251469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome.
    Gay MD; Cao H; Shivapurkar N; Dakshanamurthy S; Kallakury B; Tucker RD; Kwagyan J; Smith JP
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Astragaloside IV ameliorates diet-induced hepatic steatosis in obese mice by inhibiting intestinal FXR via intestinal flora remodeling.
    Zhai Y; Zhou W; Yan X; Qiao Y; Guan L; Zhang Z; Liu H; Jiang J; Liu J; Peng L
    Phytomedicine; 2022 Dec; 107():154444. PubMed ID: 36155217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists.
    Zhu Y; Zhang J; Min F; Yang X; Li L; Zhang Y; Hou X; Fang H
    Bioorg Med Chem Lett; 2022 Nov; 76():128993. PubMed ID: 36130662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
    Jiang C; Xie C; Li F; Zhang L; Nichols RG; Krausz KW; Cai J; Qi Y; Fang ZZ; Takahashi S; Tanaka N; Desai D; Amin SG; Albert I; Patterson AD; Gonzalez FJ
    J Clin Invest; 2015 Jan; 125(1):386-402. PubMed ID: 25500885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.